Determination of a radotinib dosage regimen based on dose–response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia

Determination of a radotinib dosage regimen based on dose–response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia

Abstract Radotinib is a second‐generation BCR‐ABL1 tyrosine kinase inhibitor approved for the treatment of chronic myeloid leukemia in chronic phase (CP‐CML). Here, using the data from a Phase 3 study conducted in patients with newly diagnosed CP‐CML, the dose–efficacy as well as dose–safety relatio...

Full description

Bibliographic Details
Main Authors: Hayeon Noh, Su Young Jung, Jae‐Yong Kwak, Sung‐Hyun Kim, Suk Joong Oh, Dae Young Zang, Suhyun Lee, Hye Lin Park, Dae Jin Jo, Jae Soo Shin, Young Rok Do, Dong‐Wook Kim, Jangik I. Lee
Format: Article
Language:English
Published: Wiley 2018-05-01
Series:Cancer Medicine
Subjects:
Chronic myeloid leukemia
dose determination
dose–response relationship
radotinib
tyrosine kinase inhibitor
Online Access:https://doi.org/10.1002/cam4.1436

Internet

https://doi.org/10.1002/cam4.1436

Similar Items